Pangen Biotech팬젠
222110 · KOSDAQ · ₩222110 · 팬젠
- Market cap
- ₩62B
- Enterprise value
- ₩59B
- P/E
- 54.7×
- P/B
- 2.0×
- Dividend yield
- 0.0%
- ROE
- 3.7%
- Net margin
- 8.0%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−46.2% from the high
₩4,220Today: ₩4,415 – ₩4,640₩8,510
Returns
- 1W−6.2%
- 1M−4.7%
- 3M−4.2%
- 6M−23.8%
- YTD−18.2%
- 1Y−25.8%
- Volume today
- 4,318
- 0.8× the 20-day average
- Traded today
- ₩19M
- Listed shares
- 13,514,509
- EPS (12 months)
- ₩84
- Earnings yield 1.8%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 39 of 100 (50 is a normal day for this stock).
- MomentumWeak-5.2% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Pangen Biotech stock overview
Pangen Biotech (팬젠, KRX: 222110) is listed on KOSDAQ, in the Biotech & Pharma sector. The company operates a Korean bio-pharmaceutical business built on its GMP-certified biologics manufacturing facilities and its proprietary PanGen CHO-TECH cell line and process technology. Its shares closed at ₩4,580 on Oct 27, 2026, down 0.65% on the day, giving it a market value of ₩62B.
Key facts
- Market cap
- ₩62B
- Sector
- Biotech & Pharma
- Latest price change
- −0.65%
- As of
- Oct 27, 2026
- Main business
- The company operates a Korean bio-pharmaceutical business built on its GMP-certified biologics manufacturing facilities and its proprietary PanGen CHO-TECH cell line and process technology.
Quick answers about Pangen Biotech
- What does Pangen Biotech do?
- The company operates a Korean bio-pharmaceutical business built on its GMP-certified biologics manufacturing facilities and its proprietary PanGen CHO-TECH cell line and process technology. Its main product is a biosimilar EPO (erythropoietin) drug for anemia in chronic kidney disease patients, sold in Korea, Malaysia, the Philippines, Saudi Arabia and Thailand, with a technology transfer agreement with a Turkish partner. It also provides contract development and manufacturing (CMO/CDO) services for biopharmaceuticals and is developing products including Factor VIII for hemophilia A, aflibercept for macular disease, an anti-SFTSV antibody and a G-CSF biosimilar.
- What is the market cap of Pangen Biotech?
- The market capitalisation of Pangen Biotech was ₩62B at the close on Oct 27, 2026.
- Who are the largest shareholders of Pangen Biotech?
- According to the latest official filings, the largest reported holders are Hugel (46.78%, as of Mar 20, 2026).
- When is the next earnings report from Pangen Biotech?
- Korean companies rarely announce results dates in advance. Based on when Pangen Biotech filed the same report in past years, its next 3q results is expected between Nov 12, 2026 and Nov 13, 2026.
Company profile
The company operates a Korean bio-pharmaceutical business built on its GMP-certified biologics manufacturing facilities and its proprietary PanGen CHO-TECH cell line and process technology. Its main product is a biosimilar EPO (erythropoietin) drug for anemia in chronic kidney disease patients, sold in Korea, Malaysia, the Philippines, Saudi Arabia and Thailand, with a technology transfer agreement with a Turkish partner. It also provides contract development and manufacturing (CMO/CDO) services for biopharmaceuticals and is developing products including Factor VIII for hemophilia A, aflibercept for macular disease, an anti-SFTSV antibody and a G-CSF biosimilar.
Written by AI from the company's latest annual report.
- Korean name
- 팬젠
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 윤재승
- Founded
- Jan 2010
- Listed
- Mar 2016
- Listed shares
- 13,514,509
- Fiscal year ends
- Month 12
- Website
- www.pangen.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Half-year report (Jun 2026)Aug 13, 2026
- Major sales or supply contractJun 22, 2026
- Major management matter relevant to investorsMay 27, 2026
- Quarterly report (Mar 2026)May 14, 2026
- Insider shareholding reportApr 24, 2026
Titles in Korean until English translations are added.
Also known as: Pangen Biotech / 팬젠 / 222110 / KRX:222110
Source: KRX statistical information